Accessibility and reading comfort

Text size

Light/Dark mode

Lines vertical spacing

Trouble using our website?
Contact us

In this page

Clinical Trial

NCT05158296 Active, Not recruiting
SIRIUS

A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene (Sirius)

Phase 2/3
Interventional

Disease

Disease type

Hereditary retinal disease

Retinitis Pigmentosa

Usher Syndrome

Patient type

Adult

Children

Inclusion / Exclusion

Opening date

08/12/2021

Closing date

31/12/2024

Inclusion criteria :

More

Exclusion criteria :

More

Funding

private

Members involved

Others investigators

Dr Katarina Stingl

Representative

Germany

Low Vision Daily Life and Patients Groups (TWG5), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)
Working Group Leader
See more

Pr Carel HOYNG

Representative

Netherlands

Genetic Diagnostics (TWG6), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)
See more

Dr Ingeborgh VAN DEN BORN

Representative

Netherlands

Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)
See more

ERN EYE member investigating site

HCP : Principal investigators

Centre for Ophthalmology, University Eye Hospital, Tübingen, Germany

Adress

Department für Augenheilkunde Tübingen Forschungsinstitut für Augenheilkunde Elfriede-Aulhorn-Str. 7

72076 Tübingen

Germany